Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,284 across all filing types
Latest filing 2025-04-02 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
董事会审计委员会关于对会计师事务所2024年度履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the performance and supervision of the external audit firm (Lixin CPA Firm) for the fiscal year 2024. It discusses the audit firm's qualifications, independence, communication with the audit committee, and the recommendation to reappoint the audit firm for 2025. The document references the audit process and the audit report issued for the 2024 annual report but does not contain the audit report itself or detailed financial statements. The document length is 1875 characters, which is relatively short and consistent with a standalone audit report or supervisory report rather than a full annual report. The content focuses on the audit committee's oversight and evaluation of the external auditor's work, which fits the definition of an Audit Report / Information filing rather than an Annual Report or Report Publication Announcement. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2024
2025-04-02 Chinese
2024年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024年度募集资金存放与使用情况专项报告" which translates to a "2024 Annual Special Report on the Deposit and Use of Raised Funds." It details the amount of funds raised, their deposit, management, and usage during the year 2024. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange related to the management and use of raised funds. The document includes detailed tables on the raised funds, their usage, balances, and investment projects funded by these raised funds. It also discusses compliance with regulatory requirements and approvals by the board. This type of document is a specialized report focused on the management and use of capital raised by the company, which aligns with a Capital/Financing Update (CAP) filing category rather than a full annual report or audit report. The document is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is Capital/Financing Update (CAP).
2025-04-02 Chinese
瑞普生物股份有限公司2024年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2024 年度内部控制自我评价报告' which translates to '2024 Annual Internal Control Self-Evaluation Report'. It is issued by the company's board of directors and discusses the evaluation of the company's internal control effectiveness as of December 31, 2024. The content includes detailed descriptions of internal control systems, evaluation scope, criteria for identifying control deficiencies, and conclusions on the effectiveness of financial and non-financial internal controls. It is a comprehensive report focused on internal control evaluation rather than a general annual report or audit report. The document length is 6406 characters, which is sufficient to contain substantive content rather than just an announcement. The nature of the report aligns with an Audit Report / Information (AR) category, as it deals with internal control evaluation and related regulatory compliance, but is not a full annual report (10-K) or a certification letter (RNS). Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-04-02 Chinese
2024年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2024 年度财务决算报告' which translates to '2024 Annual Financial Settlement Report'. It contains detailed financial data for the full fiscal year 2024, including revenue, profit, assets, liabilities, cash flow, and changes compared to previous years. The report mentions that the financial statements have been audited by an accounting firm with an unqualified opinion, indicating it is a formal audited financial report. The length of the document (7264 characters) and the presence of comprehensive financial statements and analysis confirm it is a full annual financial report rather than a brief announcement or certification. The document is not a mere announcement of report publication, nor is it a certification or a partial interim report. Therefore, it fits the definition of an Annual Report (10-K). FY 2024
2025-04-02 Chinese
2024年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2024 年度监事会工作报告' which translates to '2024 Supervisory Board Work Report'. It details the supervisory board's activities, including oversight of financial reports, internal controls, related party transactions, guarantees, and acquisitions during the 2024 fiscal year. The report includes detailed supervisory opinions on company operations, financial status, fundraising usage, acquisitions, related party transactions, guarantees, insider information management, and internal control self-assessment. It also outlines the supervisory board's work plan for 2025. The content is a comprehensive report from the supervisory board on their oversight activities and findings for the year 2024, which aligns with the nature of a Management Report (MDA) that provides detailed explanations of financial results, business trends, and outlook. It is not an announcement or a brief summary but a substantive report with detailed supervisory analysis and opinions. Therefore, the appropriate classification is Management Reports (MDA).
2025-04-02 Chinese
2024年年度报告摘要
Annual Report Classification · 100% confidence The document is titled "瑞普生物股份有限公司2024 年年度报告摘要" which translates to "Ringpu Bio Co., Ltd. 2024 Annual Report Summary." It contains detailed financial data for the year 2024, including total assets, net profit, revenue, earnings per share, and other key financial indicators. It also includes comprehensive business descriptions, industry analysis, product information, shareholder data, and notes on accounting adjustments. The document is over 14,000 characters, indicating it is a substantive report rather than a brief announcement. The presence of audited financial statements and detailed management discussion aligns with the characteristics of an Annual Report (10-K). Therefore, this document is classified as an Annual Report (10-K). FY 2024
2025-04-02 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.